Business / Finance

RSS

Fear of missing out?

Fear of missing out?

In this webinar, you will review best practices, short cuts, and tricks-of-the-trade to become more successful in developing effective HPLC methods (potency and ICH-compliant stability-indicating assays) using method templates and universal generic gradient methods.

From Pittcon 6 Nov 2019

CryoCapCell appoint Labtech as UK distributor

CryoCapCell appoint Labtech as UK distributor

Labtech International has been appointed as the UK and Ireland distributor of CryoCapCell, the France-based manufacturer of the technology-leading HPM Live μ high pressure freezing system.

From Labtech International Ltd 6 Nov 2019

Eisai transfers rights to Royalty Pharma relating to net sales of EZH2 inhibitor outside of Japan

Eisai transfers rights to Royalty Pharma relating to net sales of EZH2 inhibitor outside of Japan

Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the rights to receive royalties on the sales outside of Japan for an investigational anti-cancer agent tazemetostat (generic name) to Royalty Pharma.

5 Nov 2019

Bosch and Nanalysis announce joint product development collaboration

Bosch and Nanalysis announce joint product development collaboration

Nanalysis Scientific Corp., is pleased to announce that as of October 23rd , it has entered into a collaboration agreement with Robert Bosch GmbH to jointly develop products for the growing market industrial Nuclear Magnetic Resonance products for applications such as on-board fuel analyzers for cargo ships, driven by new international environmental standards against dirty fuels, which would be distributed by Bosch.

From Nanalysis Corp. 1 Nov 2019

Finnish biotech innovation hits billion-euro markets

Finnish biotech innovation hits billion-euro markets

Grundium, a technology company in the digital pathology sphere, has entered into a major dealership contract with Alliance Global Group.

From Grundium 24 Oct 2019

New $30M contract signed to accelerate TB vaccine development across the country

New $30M contract signed to accelerate TB vaccine development across the country

Tuberculosis (TB) is the number-one cause of death from an infectious disease in the world: In 2017, the most recent data available, 10 million people developed TB and 1.6 million died.

23 Oct 2019

Quanterix to release third quarter 2019 financial results and host conference call on November 6, 2019

Quanterix to release third quarter 2019 financial results and host conference call on November 6, 2019

Quanterix announced that it will release its financial results for third quarter 2019 after the close of trading on Wednesday, November 6, 2019.

From Quanterix 22 Oct 2019

BioStreamline project outcomes

BioStreamline project outcomes

CPI have reported successful outcomes the £11.

From Sphere Fluidics 16 Oct 2019

Sphere Fluidics expands into additional facility at Granta Park in Cambridge, UK

Sphere Fluidics expands into additional facility at Granta Park in Cambridge, UK

Sphere Fluidics, announce it has opened a new office space at Granta Park. New facilities support the Company’s accelerated expansion.

From Sphere Fluidics 16 Oct 2019

Sphere Fluidics closes a $4.8 million USD (£3.7 million) funding round

Sphere Fluidics closes a $4.8 million USD (£3.7 million) funding round

Sphere Fluidics, announced that it has closed an additional tranche of investment of $2.9 million, securing a total of $4.8 million in investment.

From Sphere Fluidics 16 Oct 2019

Sphere Fluidics hires 10 new UK and US staff in its plan to scale internationally

Sphere Fluidics hires 10 new UK and US staff in its plan to scale internationally

Sphere Fluidics, announced today that it has appointed six new employees and plans to hire four more staff in its UK and US sites.

From Sphere Fluidics 16 Oct 2019

Sphere Fluidics closes $2 million USD (c. £1.5 million GBP) investment round

Sphere Fluidics closes $2 million USD (c. £1.5 million GBP) investment round

Sphere Fluidics, announced that is has closed a $2 million (circa £1.5 million) investment round.

From Sphere Fluidics 16 Oct 2019

Pulsify Medical, a joint imec and KU Leuven spin-off, closes first-round funding, led by imec.xpand

Pulsify Medical, a joint imec and KU Leuven spin-off, closes first-round funding, led by imec.xpand

Pulsify Medical, a digital medical technology company focused on the development of wearable ultrasound patches, announced the first closing of its seed funding round, raising € 2.6 million euro.

From Imec 15 Oct 2019

Mogrify raises additional $16 million to accelerate the development of life-saving cell therapies

Mogrify raises additional $16 million to accelerate the development of life-saving cell therapies

Mogrify Ltd (Mogrify), a UK company aiming to transform the development of life-saving cell therapies, today announced the initial close of its Series A funding. The Company raised $16 million USD in this round, bringing the total investment to over $20 million USD to date.

14 Oct 2019

Impress your boss with this course

Impress your boss with this course

In this webinar, Dr. Michael W. Dong, Pittcon Short Course Instructor, will review best practices, short cuts, and tricks-of-the-trade to help pharmaceutical and other scientists to become more successful in developing effective HPLC methods (potency and ICH-compliant stability-indicating assays) using method templates and universal generic gradient methods.

From Pittcon 14 Oct 2019

EIB and Univercells sign EUR 20 million loan agreement to advance delivery of vaccines

EIB and Univercells sign EUR 20 million loan agreement to advance delivery of vaccines

The European Investment Bank and Univercells S.A have signed a EUR 20 million loan agreement to support the development of a portfolio of four essential and undersupplied vaccines to be delivered at an affordable price.

4 Oct 2019

Alpine HC completes name change to Opera Care

Alpine HC completes name change to Opera Care

Over the last three years, the Opera range of care beds and pressure care mattresses has evolved to become a core product range for our two key marketplaces; Care Homes, and Care at Home.

From Opera Care 4 Oct 2019

Entos Pharmaceuticals signs new collaboration agreement with biopharmaceutical company

Entos Pharmaceuticals signs new collaboration agreement with biopharmaceutical company

Entos Pharmaceuticals Inc. ("Entos" or the "Company"), a healthcare biotechnology company focused on the development of next-generation nucleic acid-based therapies using their Fusogenix drug delivery platform, today announced it has entered into a research, development and collaboration agreement ("Agreement") with a clinical stage biopharmaceutical company ("Partner") focused on the development of novel therapeutic compounds targeting autoimmune and inflammatory diseases.

3 Oct 2019

Nichi-Iko and Eisai sign collaboration deal for generic pharmaceutical business in China

Nichi-Iko and Eisai sign collaboration deal for generic pharmaceutical business in China

Eisai Co., Ltd. and Nichi-Iko Pharmaceutical have entered into a comprehensive collaboration agreement for the generic pharmaceutical business in China.

30 Sep 2019

Tanner Pharma Group signs a distribution agreement for partner therapeutics’ product

Tanner Pharma Group signs a distribution agreement for partner therapeutics’ product

Tanner Pharma Group, a global provider of integrated specialty access solutions, has announced the signing of a distribution agreement with Partner Therapeutics, Inc., an integrated biopharmaceutical company.

From Tanner Pharma Group 29 Aug 2019

Previous
1
...
22
23
24
25
26
27
28
...
377
Next

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.